As far as I know, there is no evidence to support the use of ADT plus an additional anti-androgen for non-metastatic, hormone sensitive PCa.
You are likely to get quite a while out of ADT alone so just ride that out and then add something when you become castrate resistant. That could be a long time from now.
It's not yet standard of care, so you would need a trial to get the drugs. I know someone who did the following trial and is so far at undetectable PSA with no current hormonal treatment:
Is it more helpful if you are metastic but hormone sensitive to Add a second - like is their studies that show it keeps people hormone sensitive longer
My Dx is very similar to yours, G9, PSA 9. No detectable spread via standard imaging. I had SBRT in June but I have been on Lupron + Erleada since March. My MO and RO (Liu and Kishan at UCLA) both said said their studies show better long term control for high Gleason grades using advanced ADT. I’m expected to be on the combo for 18-24 months. I’m not on any trial.
If your doctor won’t approve it, you may want to try the prostate oncology Specialist in Marina Del Rey California. All three doctors there think out-of-the-box and are pretty aggressive. They were doing Zytega with Adt long before it was proven in clinical trials . Lots of the guys go there. It would be interesting to see what they thought of it for you. They do phone appointments if it’s too far to travel.
The studies that Tall Allen cited show clear evidence of improvement in PSA progression. I'm wondering about the bigger picture: survival.
If I take zytiga et al now I will likely get more time before resistance. But I think the implication is that zytiga would no longer be a weapon after I become resistant. Is the overall survival better?
Both Kwon and Fong preferred deferring zytiga until later. Fong "doesn't want to use all our bullets" and Kwon suggested it is harder control after resistance (which is probably the same point as Fong's).
Personally I would shoot all of my bullets at once if it gets me longer survival. I feel like "more bullets" makes the MO feel better but is not necessarily the patient's goal (definitely not mine).
Did you get a clear data picture of what the overall survival rates were comparing ADT first and then using a 2d line (xtandi, erleada, zytiga) following psa rise while on ADT alone VS. just using ADT with a 2nd line drug right from the start? I read all of those links that TA provided but it didnt seem to take into consideration the part about adding the 2nd line drug after the ADT alone started to get rising PSA. You know what I mean? What is the average time to OS/death?
The stampede trial and some of the statistics cited on this post show results that show short life spans. I would like to see more results focused on low volume cancer. Looking at people who live closer to 8 years show similar outcomes whether they use adt alone or as the other stuff early. There is a bigger lifespan difference for people who live less than 4 years. In other words the chemo benefits or other AR drugs benefit early on but then revert back to the norm after a certain amount of time. It may not end up exactly even but it may be like 45% vs 35% OS after 8 years, so taking the extra stuff is, in a way, hoping that you will be part of that 10% grouping that keeps you alive a year longer. I realize that some of the ardent advisers on here that suggest aggressive treatment early, might take umbrage to my loose observations. I do have a chart that supports my comments. I’ll have to send it later when I unearth it.
maybe my words were too loose. I was referring to a specific study result comparing the early usage of chemo. It had increased OS but the two lines on the graph got closer together around 8 years. I cant remember when the data says about erleada, zytiga and xtandi exactly. You probably know better than me right now because I have too many other things going on in life to be as accurate as I want to be. What are your thoughts: prostatecancer.news/2017/06...
My thoughts are this: I think it is accepted that pca is an older man's disease. Starting with this assertion, the os is hard to determine because it includes deaths from all causes.
It's the css that I'm more interested in and those numbers are still not very good because the newer 2nd line adt have extended css a good bit and I believe the css is still increasing albeit at a slower rate.
For me personally, and probably a good example for the OP, I'm HS NM and currently taking Eligard with Zytiga. My psa is currently < 0.01.
You can read my bio for more details on my treatments to date.
Makes sense. What do the studies show for css advantage of adding 2d line to adt vs adt alone. Have they updated that recently based on extended data ?
I agree. I’m in the same boat as you. If seen the days from stampede but I’d like to see the current days of the study is still ongoing. I’ve also never seen clear evidence that adt alone category men got on a2d line drug immediately after their adt started failing to spies the psa. If they didn’t do that, then the study comparison would be worthless.
On a different topic.....lately I've been feeling great.....back in January (January 20th to be exact) I switch from 10mg to 5mg of daily prednisone. For several weeks I was very fatigued but I muddled through. But today I feel I'm back to normal again...I had a great workout and feeling zero fatigue.
Do you ever experience periods like this....I'm hoping it last for awhile.
My husband's journey is somewhat similar to yours. After adjuvant radiation his PSA was undetectable for nearly two years, then a recurrence. Doctors recommended Lupron at that stage, but he decided to make many holistic changes, and decided to avoid ADT as long as possible for quality of life. When PSA started rising 2 years after that, it did so quickly and scan showed Ogliomets. He is now taking both Lupron and Xtandi and is tolerating both very well. We opted for Xtandi over Zytiga because we did not want to take the steroids required with Zytiga. According to everything we read and our oncologist, that is the most current standard of care for his stage. Luckily, he is working and insurance covers most of the outrageous $11,000 per month cost of Xtandi.
I was successful in getting my doctor and insurance company to agree to Zytiga. It took some pressure on the insurance company but I think that is common: ins. co. says no, dr. challenges them, ins. co. says yes.
The cost per month is ~6.5k (I only pay $10 co-pay). (4) 250mg pills per day, 5 mg. of prednizone daily.
The effect on my PSA was dramatic. In 5 weeks it dropped from hovering at .24 to .027.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
New Canadian Member
First ever PSMA scan shows two small bone lesions 
Three strikes and...
Castrate Resistant
should I stop Zytiga early?
